Official title: Exploring the Feasibility of Cerebrospinal Fluid (CSF) Liquid Biopsy in Patients With Metastatic Solid Tumours and Leptomeningeal Disease (Cohort A), Parenchymal Brain Metastases (Cohort B), or No Evidence of Central Nervous System (CNS) Metastases (Cohort C): A Pilot Study Summary: This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease involvement, including leptomeningeal disease (Cohort A), parenchymal brain metastases (Cohort B), and no evidence of CNS metastases (Cohort C). Conditions: Solid Tumor Malignancies, Brain Metastasases, Leptomeningeal Disease (LMD) Study type: INTERVENTIONAL Primary purpose: BASIC SCIENCE Phases: NA Enrollment: 60 (ESTIMATED) Status: RECRUITING Completion: 2026-12 (ESTIMATED)
ClinicalTrials.gov published a clinical update in Oncology on 17 Mar 2026.
The item focuses on CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases.
Review the original article for the full source wording and details.